TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

@article{Quoix2016TG4010IA,
  title={TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.},
  author={Elisabeth A Quoix and Herv{\'e} L{\'e}na and Gy{\"o}rgy Losonczy and Fr{\'e}d{\'e}ric Forget and Christos Choua{\"i}d and Zsolt Papai and Radj Gervais and Christian H Ottensmeier and Aleksandra Szczęsna and Andrzej Każarnowicz and Joseph Thaddeus Beck and V. Westeel and E Felip and Didier Debieuvre and Anne Madroszyk and Julien Adam and Gis{\`e}le Lacoste and Annette Tavernaro and B{\'e}rang{\`e}re Bastien and C{\'e}line Halluard and Tania Palanch{\'e} and Jean Marc Limacher},
  journal={The Lancet. Oncology},
  year={2016},
  volume={17 2},
  pages={212-223}
}
BACKGROUND MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In a previous study, TG4010 combined with chemotherapy showed activity in non-small-cell lung cancer and the baseline value of CD16, CD56, CD69 triple-positive activated lymphocytes (TrPAL) was shown to be potentially predictive of TG4010 efficacy. In this phase 2b part of the phase 2b/3 TIME trial, we… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 20 times over the past 90 days. VIEW TWEETS
34 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…